NASDAQ : VOGX

Vogenx, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 20.25 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 300.82M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.

Details

NameVogenx, Inc.
SectorHealthcare
IndustryBiotechnology
Employees5
Founded2021
Ipo Date2026-08-12
CeoJames Green
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price13.00
IsinUS92859A1060
Cusip92859A106
Cik1903784
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
James GreenPresident, Chief Executive Officer and Chairman
Steven R. DelmarChief Financial Officer, Corporate Secretary and Director
Dr. William Wilkison Ph.D.Chief Scientific Officer, Chair of Scientific Advisory Board and Director

Contact

Address3901 Barrett Drive, Suite 300, Raleigh, North Carolina 27609, United States
Phone919 659 5677
Websitehttps://vogenx.com